Teladoc Health heads into its July 28 earnings report with options traders unusually bullish and short sellers quietly trimming positions — a rare alignment of bullish signals for a stock that has spent much of 2026 under heavy scepticism.
The most striking data point this week is the options market. Call demand has surged to its most extreme level relative to recent history, with the put/call ratio dropping to 0.36 — more than two standard deviations below its 20-day average of 0.41. That reading is the lowest in months and sits near the bottom of the 52-week range of 0.28–1.03. Options traders are positioning for upside ahead of next week's print, not protection. The shift is particularly notable given the stock was trading in the 0.42 PCR band consistently through late June; the move lower accelerated sharply in the past two sessions.
Short positioning tells a supporting story, though with more nuance. SI runs at roughly 15% of the free float — meaningfully elevated and a genuine constraint on the upside narrative — but the trend has shifted. Shorts peaked near 30 million shares in late June and early July, and have since retreated to around 26.6 million. That is a drop of roughly 12% in borrowed shares over three weeks, with the pace of covering accelerating after July 8. Borrow cost remains trivial at 0.44%, and availability is wide at nearly 390% of short interest — meaning there are close to four shares available to borrow for every one currently lent out. The lending market is not tight; shorts who want to press the trade face no friction in doing so, which makes the active covering more meaningful. It reflects a directional call, not a technical squeeze.
The Street has turned incrementally more positive, even if the consensus remains divided. Canaccord Genuity raised its target from $10 to $11 on July 21 — the day before this note — maintaining a Buy. Bank of America lifted its target from $9 to $10.50 on July 7, also keeping Buy. Those are the two most recent moves, and both point higher. However, the mean price target of $7.71 still sits well below the current price of $9.71, dragged down by a cluster of Neutral and In-Line ratings from Citi, JPMorgan, Evercore, and Barclays, most of whom hold targets in the $6–$7 range that now look stale relative to the stock's 20% rally over the past month. The bear case centres on BetterHelp's growth slowdown, Integrated Care revenue deceleration, and AI investment drag on margins. The bull case rests on Teladoc's positioning in employer and health plan channels and the emerging coverage expansion for BetterHelp services. EV/EBITDA has crept up to 6.9x on the recent price move — not stretched by any absolute measure, but the market is now pricing in execution.
Institutional positioning adds one genuinely interesting detail. Voss Capital filed a position of 8.3 million shares as of June 17, up from effectively nothing — implying a fresh stake of more than 4 million shares in Q2. That puts an active manager with a known activist/value orientation among the top three shareholders. Combined with BlackRock adding 500,000 shares through June 30, institutional accumulation has been real, not passive drift.
Earnings reactions have been muted in the recent past: the last two prints each moved the stock around 1% on the day, though both generated 13–16% five-day follow-through to the upside — suggesting the market's response has played out over the week rather than overnight. With call positioning at a multi-month extreme and shorts actively covering into the event, what matters next week is whether management can provide enough clarity on BetterHelp trajectory and margin outlook to justify the 20% re-rating the stock has already received.
See the live data behind this article on ORTEX.
Open TDOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
